Head-to-head · WeighScore
altRX vs Omada Health
The verdict
altRX takes it — 71.4/100 to 55.6/100.
altRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. altRX is a dual-modality telehealth platform offering compounded GLP-1s plus all four brand-name FDA-approved options — Mounjaro, Ozempic, Wegovy, and Zepbound — the most comprehensive brand-name lineup in…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | altRX | Omada Health |
|---|---|---|
| WeighScore | 71.4/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #92 | #435 |
| Semaglutide | $149/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $249/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #92 · C
Strengths
- Offers all four brand-name FDA-approved GLP-1s (Mounjaro, Ozempic, Wegovy, Zepbound) — the most comprehensive brand-name access we've reviewed
- LegitScript Certified with a publicly verifiable seal
- Publishes the FDA compounded-medication disclaimer
- Transparent pricing across all six product tiers (compounded plus four brand-name)
- All-inclusive pricing — consult, prescription, and shipping with no hidden fees
Where it loses points
- States-served list not disclosed
- 503A/503B pharmacy partner not named (only 'multiple USA-certified pharmacies')
- 503A vs 503B designation not specified
- No named medical director
- Corporate physical address not disclosed
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.